Table 3

Rates of events per visit for ALT and/or AST abnormalities >2× upper limit of normal

DMARDs other than MTX or LEFMTX aloneLEF aloneMTX+LEFTotal
All oral DMARDs0.8%0.3%0.3%0.9%0.4%
12/144131/104053/9708/85754/13673
ADA1.5%0.7%0.0%0.0%0.9%
9/60411/14720/1760/4720/2299
ETN0.9%0.4%0.4%1.1%0.6%
14/15139/24771/2471/8825/4325
INF1.7%0.7%0.9%0.0%0.9%
14/84626/35524/4570/11444/4964
Total1.1%0.4%0.4%0.8%0.6%
49/440477/179068/18509/1106143/25266
p Value*0.21850.00230.58210.9977<0.001.
  • * The p values compare the tumour necrosis factor inhibitor and all oral DMARDs within each background group.

  • ADA, adalimumab; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DMARDs, disease-modifying antirheumatic agents; ETN, etanercept; INF, infliximab; LEF, leflunomide; MTX, methotrexate.